Background Adjuvant radiotherapy for rectal cancer has beenextensively studied, but no trial has unequivocally demonstratedimproved overall survival with radiotherapy, despite a reductionin the rate of local recurrence.
Methods Between March 1987 and February 1990, we randomly assigned1168 patients younger than 80 years of age who had resectablerectal cancer to undergo preoperative irradiation (25 Gy deliveredin five fractions in one week) followed by surgery within oneweek or to have surgery alone.
Results The irradiation did not increase postoperative mortality.After five years of follow-up, the rate of local recurrencewas 11 percent (63 of 553 patients) in the group that receivedradiotherapy before surgery and 27 percent (150 of 557) in thegroup treated with surgery alone (P<0.001). This differencewas found in all subgroups defined according to Dukes' stage.The overall five-year survival rate was 58 percent in the radiotherapy-plus-surgerygroup and 48 percent in the surgery-alone group (P = 0.004).The cancer-specific survival rates at nine years among patientstreated with curative resection were 74 percent and 65 percent,respectively (P = 0.002).
Conclusions A short-term regimen of high-dose preoperative radiotherapyreduces rates of local recurrence and improves survival amongpatients with resectable rectal cancer.
The value of adding radiotherapy to surgery in the treatmentof patients with resectable rectal cancer has been assessedin trials using either preoperative1,2,3,4,5,6 or postoperative7,8,9,10irradiation. Lower rates of local recurrence have been foundwith radiotherapy in most of these trials, especially thoseusing preoperative irradiation. In a randomized trial in theUppsala region of Sweden, it was found that preoperative irradiationwas more effective than postoperative therapy, even though thedose of postoperative radiation was higher.11 However, no trialhas yet shown that, as compared with surgery alone, adjuvantpreoperative radiotherapy significantly improves overall survival.1,2,6,12A meta-analysis of all the controlled trials on this subjectpublished before 1986 found a marginally positive effect ofradiotherapy on survival.13 A survival benefit was also foundwith a combination of postoperative radiotherapy and prolongedchemotherapy9; in another trial, postoperative chemotherapyalone, but not radiotherapy, improved survival.8
Preoperative irradiation is more "dose-effective" than postoperativeradiotherapy14; that is, a higher dose is needed postoperativelyto reduce rates of local recurrence to the same extent as preoperativeradiation. Nevertheless, preoperative treatment has not beenroutinely recommended,15 mainly because it has not been shownto improve overall survival and because in some trials it hasbeen associated with increased postoperative mortality.2,6
We conducted the present trial to determine whether preoperativeradiotherapy with a three-beam or four-beam technique couldbe given to patients younger than 80 years of age without increasingpostoperative mortality, to substantiate the previously observedreduction in the rate of local recurrence with radiotherapy,and to investigate the effects of the treatment on survival.In this report, we present rates of local recurrence and survivalafter a minimal follow-up of five years. The local-recurrencerates after a minimum of two years of follow-up have been reportedpreviously.16
Methods
Randomization
Patients were randomly assigned to treatment groups, with stratificationaccording to hospital, by telephone contact with the trial centerin one of the six Swedish health care regions. The patientswere assigned either to one week of preoperative irradiation,followed by surgery within the next week (radiotherapy-plus-surgerygroup), or to surgery with no additional radiotherapy (surgery-alonegroup).
Sample Size
In order to detect a reduction in the rate of local recurrencefrom 20 percent to 10 percent with 90 percent probability anda 5 percent significance level, we calculated that a total of475 patients had to be recruited. To detect an increase in postoperativemortality from 2 percent to 5 percent (again with 90 percentprobability and a 5 percent significance level), we needed torecruit 750 patients. To show an increase of 10 percentage pointsin survival (from 50 percent to 60 percent) after five yearswith 80 percent probability and a 5 percent significance level,750 curatively resected patients had to be recruited. Assuminga 10 percent dropout rate and assuming that approximately 20percent of the patients would be found to have metastatic diseaseat the time of surgery or would have a noncurative local resection,we had to enroll at least 1100 patients.
Patients
Between March 1987 and February 1990, we recruited patientswith resectable rectal carcinoma for whom abdominal surgerywas planned. Patients were eligible for the trial if they wereless than 80 years old, had a histopathologically proved adenocarcinomasituated below the promontory, as shown on a lateral projectionon barium enema, and gave informed consent for their participation.The protocol was approved by the regional ethics committees.
The criteria for exclusion were a locally nonresectable tumor;a plan to perform only local excision; known metastatic disease;previous radiotherapy to the pelvis; and other malignant disease(except squamous-cell carcinoma of the skin).
Of 1168 patients from 70 hospitals throughout Sweden who wererandomly assigned to treatment groups, 908 (78 percent; 454in each group) were treated with curative intent (Table 1).The patients' characteristics are described in the first reportfrom this trial.17 There is some overlap between the currentSwedish Rectal Cancer Trial and the so-called Stockholm II trial,18in that 316 patients who were enrolled in Stockholm from March1987 through February 1990 are also included in the currenttrial, whereas the patients enrolled after February 1990 inStockholm (238 patients) are not included in this analysis.
The clinical target volume, estimated according to the InternationalCommission on Radiation Units and Measurements report 50 (ICRU50), included the anal canal, the primary tumor, the mesorectaland presacral lymph nodes, the lymph nodes along the internaliliac vessels, the lumbar lymph nodes up to the level of theupper border of the fifth lumbar vertebra, and the lymph nodesat the obturator foramina. The plan was to deliver treatmentwith three beams with the patient in a prone position, as previouslydescribed,19 or with a four-beam "box" technique with the patientlying either supine or prone. Shielding of tissues not at riskof containing tumor cells was stipulated in the protocol.20
The protocol called for the delivery of 25 Gy in five fractionswith 5 to 16 megavoltage photons in one week. The dose was definedas that delivered at the intersection of the central axes ofthe three or four beams. This radiation schedule was designedto correspond approximately to a dose of 45 Gy given with conventionalfractionation (i.e., 2 Gy daily five days a week). Originally,the cumulative-radiation-effect (CRE) formula of Kirk et al.,21with corrections for late effects as described by Turesson andNotter,22 was used to estimate short-term and late effects ofdifferent radiation schemes. According to the original CRE concept,this treatment corresponds approximately to a total dose of42 Gy when given in fractions of 2 Gy five times a week. Withcorrections for late effects,22 the corresponding dose is approximately48 Gy. Using the linear–quadratic time model (LQ formula23),a dose of five fractions of 5 Gy each also corresponds to approximately42 to 50 Gy in 2-Gy fractions. Uncertainties about the precisecorrespondence remain, however, because of insufficient knowledgeof the size of the coefficients of the LQ formula for varioustumors and normal tissues.14,20
Surgery and Histopathological Analysis
Anterior resection or abdominoperineal excision was to be performedwithin one week after the completion of radiotherapy. Surgerywas considered locally curative if both the surgeon and thehistopathologist considered the margins of the resected tissueto be free of tumor, even if the bowel was perforated duringsurgery. The locally curative nature of surgery was definedas uncertain when either the surgeon or the pathologist reporteda questionable margin. In all other cases, the treatment wasconsidered not locally curative.
The resected specimens were examined by a pathologist in theregion where the center was located, who classified the tumoraccording to the original staging system of Dukes and Bussey.24When the rate of local recurrence was calculated in relationto tumor stage, the local Dukes' stage was used even when distantmetastases were known to exist. The pathologist also classifiedthe resection as locally curative, of uncertain curativeness,or not locally curative. The treatment was considered curativeif the resection was locally curative and no distant metastaseswere found during surgery.
Follow-Up
A clinical evaluation twice a year during the first five yearsafter surgery was stipulated in the protocol. Any clinicallydetectable tumor, whether morphologically verified or not, withinthe dorsal parts of the pelvis, including the urinary bladder,was considered a local recurrence. Laboratory tests, imaging,and biochemical tests were performed only if a local or distantrecurrence was suspected.
All case-record forms were checked by an independent observeragainst the clinical records during an audit in 1995. The causesof death of all patients who died were checked against the NationalCauses of Death Registry by computerized linkage. Living patientshad been followed up for a median of 75 months (range, 60 to96 months) as of March 1995.
Statistical Analysis
The significance of differences in proportions was calculatedwith the chi-square test, and that of differences between meanswith Student's t-test. P values of less than 0.05 were consideredto indicate statistical significance. Analyses of postoperativemortality and overall survival were based on all eligible patients(Table 1), whereas rates of postoperative morbidity and localrecurrence were based only on those who underwent resection.All comparisons between the treatment groups were made on theintention-to-treat principle. Survival and cumulative incidencewere estimated with actuarial methods. Distributions of factorswere analyzed with the log-rank test. A multivariate analysisof survival according to assigned treatment was performed withuse of the Cox proportional-hazards regression model, with boththe assigned treatment and the Dukes' stage included as independentvariables.
Before the trial started, it was stipulated that postoperativemortality and morbidity should be reported when the last patienthad been enrolled. Rates of local recurrence were to be analyzedafter two and five years of follow-up, and survival after aminimum of five years.
Results
Treatment and Postoperative Mortality
Of the 573 eligible patients who were randomly assigned to receivepreoperative radiotherapy, 555 (97 percent) received up to 25Gy of irradiation; no patient in the surgery-alone group receivedpreoperative radiotherapy. In 3 percent of the patients in bothgroups, the tumor was not resected, because it either was unresectableor was found to be metastatic at surgery (Table 1). Similarproportions in the two groups underwent surgery classified asnoncurative (Table 1). In-hospital mortality was 4 percent (22of 573 patients) in the radiotherapy-plus-surgery group and3 percent (15 of 574) in the surgery-alone group (P = 0.3).However, in the group of patients irradiated with two beams,in-hospital mortality was considerably higher (15 percent [7of 48 patients]) than in those irradiated as stipulated in theprotocol with three or four beams (3 percent [13 of 507], P<0.001).The distribution of the Dukes' stages in two groups is shownin Table 2 and described in detail in our first report.17
Table 2. Rates of Local Recurrence According to Dukes' Stage and Surgical Outcome among Patients with Resected Tumors Assigned to Radiotherapy plus Surgery or Surgery Alone.
Rates of Local Recurrence
After follow-up for a minimum of five years, the local-recurrencerates were significantly lower after combined radiotherapy andsurgery than after surgery alone in all groups of patients (Table 2).In the irradiated group, 11 percent (63 of 553 patients)had a local recurrence, as compared with 27 percent (150 of557) in the group undergoing surgery alone (P<0.001). Thecorresponding figures were 9 percent (41 of 454 patients) and23 percent (106 of 454) among the curatively treated patients(P<0.001). As shown in Table 2, a significant reduction inthe rate of local recurrence was found among patients with allthree Dukes' stages who underwent preoperative radiotherapy.Figure 1 shows the proportion of local failures observed afterdifferent amounts of follow-up. The reduction in the rate oflocal recurrence with radiotherapy was 58 percent (95 percentconfidence interval, 46 to 69 percent). The same reduction inthe rate of local recurrence with the addition of radiotherapywas also noted after different surgical procedures (Table 3).
Table 3. Rates of Local Recurrence According to Surgical Procedure among Patients Assigned to Radiotherapy plus Surgery or Surgery Alone.
Overall Rates of Recurrence
At follow-up, 28 percent of the curatively treated patients(125 of 454) in the radiotherapy-plus-surgery group had signsof recurrent disease, as compared with 38 percent (171 of 454)in the surgery-alone group (P<0.001). In the radiotherapy-plus-surgerygroup, 22 patients (5 percent) had only a local recurrence,and 84 (19 percent) had only distant metastases. The correspondingfigures in the surgery-alone group were 59 patients (13 percent)and 65 patients (14 percent), respectively. Both local and distantrecurrences were seen in 19 patients (4 percent) in the radiotherapy-plus-surgerygroup and in 47 patients (10 percent) in the surgery-alone group.
Survival
Both overall survival in all patients (Figure 2) and cancer-specificsurvival (Figure 3) among patients in whom curative surgerywas performed were significantly higher in the radiotherapy-plus-surgerygroup than in the group treated with surgery alone. The relativehazard of death from all causes in the radiotherapy-plus-surgerygroup was 0.79 (95 percent confidence interval, 0.66 to 0.92),and that of death due to cancer was 0.69 (95 percent confidenceinterval, 0.55 to 0.83). Overall five-year survival rates inthese two groups were 58 percent (95 percent confidence interval,54 to 62 percent) and 48 percent (95 percent confidence interval,44 to 52 percent), respectively (P = 0.004); radiotherapy wasthus associated with an increase of 21 percent (95 percent confidenceinterval, 8 to 34 percent) in overall survival.
Figure 3. Cancer-Specific Survival among All Patients Undergoing Curative Operations, According to Dukes' Stage and Treatment Assignment.
The bars indicate 95 percent confidence limits.
As shown in Table 2, more patients had a tumor in Dukes' stageA or B in the radiotherapy-plus-surgery group than in the surgery-alonegroup, a statistically significant difference (P = 0.008), whichis most likely due to a "down-staging" effect of preoperativeirradiation.17 To test whether the survival difference persistedafter adjustment for the imbalance in Dukes' stage — thatis, whether it was due to chance — we performed a Coxregression analysis including age, sex, Dukes' stage, and treatmentgroup as variables. In this analysis the relative hazard ofdeath from all causes changed only marginally, to 0.81 (95 percentconfidence interval, 0.67 to 0.94).
Discussion
We designed this trial to detect even a small but clinicallyrelevant survival benefit associated with the use of preoperativeradiotherapy in patients with resectable rectal cancer. We foundthat preoperative radiotherapy not only reduced the rate oflocal recurrences but also improved survival. Moreover, thesurvival benefit, 21 percent (95 percent confidence interval,8 to 34 percent), is of the same magnitude as that reportedby three North American trials of postoperative chemotherapy8or chemoradiotherapy9,10 in rectal cancer and is not significantlydifferent from that obtained with chemotherapy alone in patientswith Dukes' stage C colon cancer.25,26
The results of randomized trials worldwide of adjuvant radiotherapyfor rectal cancer indicate that preoperative radiotherapy ismore effective than postoperative radiation in reducing ratesof local failure.14,27 If the dose of radiation is moderatelyhigh, the reduction is at least 50 percent,1,2,4,6 as we alsofound. A reduction of this magnitude has not been found withlower preoperative doses3,5,28,29 or with even higher dosesdelivered postoperatively.7,8,9,10 Only one trial has comparedpreoperative and postoperative radiotherapy; the patients givenpreoperative radiotherapy received the same dose as those inour study.11 The patients who were treated postoperatively (onlythose in this group with tumors in Dukes' stage B or C underwentradiotherapy) received the highest dose used in an adjuvantsetting (60 Gy given over seven to eight weeks). Nevertheless,the preoperatively irradiated group had a significantly lowerrate of local recurrence (12 percent vs. 25 percent, P = 0.02).11,30
Concern has been expressed about the short- and long-term toxiceffects of high fractional doses of radiation.31 Doses higherthan 1.8 to 2.0 Gy per fraction, such as the 5-Gy fraction administeredin this and other trials,2,4,6 may lower the therapeutic ratio,particularly with respect to late toxic effects.31 Higher fractionaldoses imply shorter treatment periods and thus have practicaland economic advantages. The tumor-cell–killing effectof a dose of 25 Gy in one week (5 Gy daily for five days) correspondsapproximately to that of 42 to 50 Gy (2 Gy daily for five daysa week) over four to five weeks according to older conceptssuch as the CRE formula21 used in our study, the nominal standarddose,32 and the possibly more accurate LQ formula.23
We stress the importance of the irradiation technique, whichmust prevent unnecessary irradiation of tissues outside thetumor-containing areas. Our results and those of the Uppsalatrial11 show that five doses of 5 Gy each can be given preoperativelyto patients younger than 80 years without any significant increasein the number of complications in the immediate postoperativeperiod. The toxicity associated with a large radiation volumewas our chief reason for undertaking this study. Two beams cannotspare surrounding tissues to the same extent as three or fourbeams.20 Increased postoperative mortality, mainly among elderlypatients, was found in both the Stockholm–Malmö trial,6in which five fractional doses of 5 Gy each were also given,but with two beams extending above L2, and the British ImperialCancer Research Fund trial,2 in which three 5-Gy fractions weregiven with anterior–posterior beams to the entire pelviccavity. In another British trial, by the Northwest Region RectalCancer Group, four 5-Gy fractions were given with a rotationalthree-field wedge technique without any increase in postoperativemortality, further emphasizing the importance of the radiationtechnique.4
It is too early to evaluate the late adverse effects of theshort-term, high-dose preoperative radiotherapy protocol usedin this trial. A preliminary analysis of responses to a questionnaireabout anal function sent to all recurrence-free patients whohad a sphincter-saving procedure and were alive in 1996 (atleast five years after treatment) indicates that patients whounderwent irradiation have more problems with the number ofbowel movements, incontinence, urgency, and soiling than thosewho were assigned to surgery alone. However, their quality oflife is good and is not significantly different from that ofthe patients who had surgery alone (unpublished data). To minimizedisturbance of bowel function, the routine inclusion of theanal canal in the irradiated volume in proximal rectal tumors,as was standard in our trial, should probably be avoided. Analfunction after postoperative chemoradiotherapy has not beenstudied prospectively, but recent data suggest a worse outcomeafter postoperative than after preoperative treatment.33,34
Prospective follow-up over a 10-year period (still a ratherlimited period) in the Uppsala trial (in which five fractionsof 5 Gy each were delivered with three beams, with the upperlevel of the irradiated field at mid-L3) showed no increasedrisk of late adverse effects.28 The projected 10-year rate ofsmall-bowel obstruction was 5 percent among patients irradiatedpreoperatively, 6 percent among nonirradiated patients, and11 percent among those who received postoperative irradiation(30 fractions of 2 Gy each). The number of patients followedfor more than 10 years was small, however. The Stockholm–Malmötrial, in which the radiation dose was the same but the irradiatedvolume was considerably larger (upper level above L2 with twobeams), found an increase in thromboembolic events, femoral-neckand pelvic fractures, delayed perineal wound healing, and intestinalobstruction.18 In that study, pelvic fractures occurred onlyamong the patients treated in Stockholm, perhaps because thestipulated shielding was not used routinely in Stockholm. Inthe Stockholm II trial, which partly overlaps with our trial,there was a significantly increased rate of hospitalizationfor delayed perineal wound healing, but not for other complications.18
As compared with the group treated with surgery alone, therewere significantly more patients in Dukes' stage A and fewerpatients in Dukes' stage C in the group given preoperative radiotherapy(P = 0.008). This is most likely due to a down-staging effectof radiotherapy. Down-staging has also been observed in trialswith longer treatment periods and with an interval of severalweeks between the end of irradiation and surgery.1,3 Analysisof more than 1500 patients, including those in the present trialand the Uppsala trial,11 has shown that the tumors were significantlysmaller and the number of positive lymph nodes fewer in thepreoperatively irradiated group.35 This down-staging effectmay arouse concern on the part of physicians who routinely administerpostoperative chemotherapy to patients with Dukes' stage B orC tumors. However, when we analyzed survival separately amongpatients with the various Dukes' stages, we found improvementin all groups, although a statistically significant effect oftreatment was evident only in the group with tumors in Dukes'stage C (Figure 2). Moreover, this benefit persisted when theDukes' stage was taken into account in a Cox regression model.
Should all patients with a primary resectable rectal cancerreceive preoperative radiotherapy? Some surgeons claim theycan achieve very low rates of local recurrence and good survivalwithout radiotherapy, provided the surgical technique is optimal.36In this trial, the local-recurrence rate of 27 percent afterfive years of follow-up in the surgery-alone group is similarto the findings in all the other controlled trials on this topic,in which the local-recurrence rates in the surgery-alone groupshave varied from 20 percent to 40 percent (average, 28 percent).1,3,4,5,6,7,10,12,26,27These figures are unacceptably high in the light of the morbidityassociated with local failure. Optimal surgery, such as totalmesorectal excision for rectal cancer,36 might yield lower ratesof local recurrence than standard surgery, but no randomizedcomparison of these surgical methods has been reported. Perhapsa combination of radiotherapy and total mesorectal excisioncan improve the results even further.37
Of concern in all cases in which neoadjuvant treatment is usedis the overtreatment of patients with Dukes' stage A lesions,which can be recognized fairly easily and with reasonably highaccuracy by preoperative endorectal ultrasonography.38 However,in this trial the proportional reduction in the rates of localrecurrence was of the same magnitude among patients with tumorsin all Dukes' stages. This has also been reported from the Stockholm–Malmötrial.6 If surgery is optimal, preoperative ultrasonographycan be used to exclude patients from preoperative radiotherapy.Nevertheless, in patients with an anatomically very low tumor— especially in men in whom an abdominoperineal excisionis planned — preoperative radiotherapy should be consideredirrespective of tumor size, since such patients are at highrisk for local failure even if surgery is optimal.
Supported by a grant (1921-B91-08XBC) from the Swedish CancerSociety, by the Stockholm Cancer Society, and by the Jerzy andEva Cederbaum Minervafond.
We are indebted to Johan Bring at the Regional Oncological Centerin the Uppsala–Örebro health care region for statisticalassistance.
* Participating investigators are listed in the Appendix.
Source Information
Address reprint requests to Dr. Lars Påhlman at the Department of Surgery, Akademiska sjukhuset, University of Uppsala, S-751 85 Uppsala, Sweden. Dr. Påhlman and the Writing Committee assume responsibility for the overall content of the manuscript.
References
Gérard A, Buyse M, Nordlinger B, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer: final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208:606-614. [Medline]
Goldberg PA, Nicholls RJ, Porter NH, Love S, Grimsey JE. Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment failure. Eur J Cancer 1994;30:1602-1606. [CrossRef]
Horn A, Halvorsen JF, Dahl O. Preoperative radiotherapy in operable rectal cancer. Dis Colon Rectum 1990;33:823-828. [CrossRef][Medline]
Jones DJ, Zaloudik J, James RD, Haboubi N, Moore M, Schofield PF. Predicting local recurrence of carcinoma of the rectum after preoperative radiotherapy and surgery. Br J Surg 1989;76:1172-1175. [Medline]
Rider WD, Palmer JA, Mahoney LJ, Robertson CT. Preoperative irradiation in operable cancer of the rectum: report of the Toronto trial. Can J Surg 1977;20:335-338. [Medline]
Stockholm Rectal Cancer Study Group. Preoperative short-term radiation therapy in operable rectal carcinoma: a prospective randomized trial. Cancer 1990;66:49-55. [CrossRef][Medline]
Balslev I, Pedersen M, Teglbjaerg PS, et al. Postoperative radiotherapy in Dukes' B and C carcinoma of the rectum and rectosigmoid: a randomized multicenter study. Cancer 1986;58:22-28. [CrossRef][Medline]
Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988;80:21-29. [Free Full Text]
Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465-1472. [Abstract]
Krook JE, Moertel CG, Gunderson LL, et al. Effective adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-715. [Abstract]
Påhlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma: report from a randomized multicenter trial. Ann Surg 1990;211:187-195. [Medline]
Marsh PJ, James RD, Schofield PF. Adjuvant preoperative radiotherapy for locally advanced rectal carcinoma: results of a prospective, randomized trial. Dis Colon Rectum 1994;37:1205-1214. [CrossRef][Medline]
Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don't know. JAMA 1988;259:3571-3578. [Free Full Text]
Glimelius B, Isacsson U, Jung B, Påhlman L. Radiotherapy in addition to radical surgery in rectal cancer — evidence for a dose-response effect favouring preoperative treatment. Int J Radiat Oncol Biol Phys (in press).
Clinical announcement 1991: adjuvant therapy for rectal cancer. Bethesda, Md.: National Cancer Institute, 1991.
Swedish Rectal Cancer Trial. Local recurrence rate in a randomised multicentre trial of preoperative radiotherapy compared with operation alone in resectable rectal carcinoma. Eur J Surg 1996;162:397-402. [Medline]
Swedish Rectal Cancer Trial. Initial report from a Swedish multicentre study examining the role of preoperative irradiation in the treatment of patients with resectable rectal carcinoma. Br J Surg 1993;80:1333-1336. [Medline]
Holm T, Singnomklao T, Rutqvist LE, Cedermark B. Adjuvant preoperative radiotherapy in patients with rectal carcinoma: adverse effects during long term follow-up of two randomized trials. Cancer 1996;78:968-976. [CrossRef][Medline]
Glimelius B, Graffman S, Påhlman L, Rimsten Å, Wilander E. Preoperative irradiation with high-dose fractionation in adenocarcinoma of the rectum and rectosigmoid. Acta Radiol Oncol 1982;21:373-379. [Medline]
Frykholm GJ, Isacsson U, Nygard K, et al. Preoperative radiotherapy in rectal carcinoma -- aspects of acute adverse effects and radiation technique. Int J Radiat Oncol Biol Phys 1996;35:1039-1048. [CrossRef][Medline]
Turesson I, Notter G. The influence of fraction size in radiotherapy on the late normal tissue reaction. Int J Radiat Oncol Biol Phys 1984;10:593-8, 599. [Medline]
Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-694. [Free Full Text]
Dukes CE, Bussey HJR. The spread of rectal cancer and its effect on prognosis. Br J Cancer 1958;12:309-320. [Medline]
Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil as adjuvant therapy in resected colon carcinoma. N Engl J Med 1990;322:352-358. [Abstract]
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-944. [CrossRef][Medline]
Påhlman L, Glimelius B. The value of adjuvant radio(chemo)therapy for rectal cancer. Eur J Cancer 1995;31:1347-1350. [CrossRef]
Duncan W. Adjuvant radiotherapy in rectal cancer: the MRC trials. Br J Surg 1985;72:Suppl:S59-S62.
Kligerman MM, Urdaneta N, Knowlton A, Vidone R, Hartman PV, Vera R. Preoperative irradiation of rectosigmoid carcinoma including its regional lymph nodes. AJR Am J Roentgenol 1972;114:498-503.
Frykholm GJ, Glimelius B, Påhlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993;36:564-572. [CrossRef][Medline]
Fletcher GH. Hypofractionation: lessons from complications. Radiother Oncol 1991;20:10-15. [CrossRef][Medline]
Ellis F. Dose, time and fractionation: a clinical hypothesis. Clin Radiol 1969;20:1-7. [CrossRef][Medline]
Graf W, Ekström K, Glimelius B, Påhlman L. A pilot study of factors influencing bowel function after colorectal anastomosis. Dis Colon Rectum 1996;39:744-749. [CrossRef][Medline]
Lewis WG, Williamson MER, Kuzu A, et al. Potential disadvantages of post-operative adjuvant radiotherapy after anterior resection for rectal cancer: a pilot study of sphincter function, rectal capacity and clinical outcome. Int J Colorectal Dis 1995;10:133-137. [CrossRef][Medline]
Graf W, Dahlberg M, Osman M, Holmberg L, Påhlman L, Glimelius B. Do short-term preoperative radiotherapy schedules for rectal cancer result in down staging? Radiother Oncol (in press).
Glimelius B, Isacsson U, Jung B, Påhlman L. Radiotherapy in addition to radical surgery in rectal cancer. Acta Oncol 1995;34:565-570. [Medline]
Lindmark G, Elvin A, Påhlman L, Glimelius B. The value of endosonography in preoperative staging of rectal cancer. Int J Colorectal Dis 1992;7:162-166. [CrossRef][Medline]
Appendix
This study was performed in collaboration with the six RegionalOncological Centers in Sweden.
The study coordinators were L. Påhlman and B. Glimelius.The participating hospitals and clinicians were as follows:Stockholm–Gotland health care region — Karolinska:B. Cedermark, G. Lundell, C. Rubio, L.E. Rutqvist, N. Wilking,and Å. Öst; Huddinge: B. Brismar and S. Ewerth; Danderyd:L. Forsgren and C. Johansson; Södersjukhuset: I. Magnusson,P. Sundelin, C. Svensson, and B. Törnberg; Sabbatsberg:T. Theve; Nacka Sjukhus: G. Fenyö; Löwenströmska:S.O. Svensson; Ersta: S. Goldman and K. Molin; Visby: S. Bark,M. Sundblad; St. Göran: J. Dalén, C. Lindholmer,and B. Robertsson; Södertälje: U. Öhman; Norrtälje:S.-E. Nilsson; Uppsala–Örebro health care region— Akademiska: M. Dahlberg, B. Glimelius, W. Graf, G. Jansson-Frykholm,G. Lindmark, and L. Påhlman; Samariterhemmet: M. Westman;Enköping: H. Liljeholm; Falun: O. Bendtsen, U. Ljungquist,and A. Nihlberg; Mora: R. Heuman; Ludvika: T. Lorentz; Avesta:A. Bisgaard-Pedersen; Gävle: S. Bergström, M. Krog,and T. Tuvesson; Sandviken: P. Edman; Söderhamn: C. Lindström;Bollnäs: B. Sandhammar; Hudiksvall: G. Tydén; Karlstad:L. Bergman, L.-K. Enander, and I. Underskog; Säffle: H.Sellström; Kristinehamn: P. Armatys; Arvika: P. Moell;Eskilstuna: R. Hellberg and B. Stenstam; Kullbergska: G. Dafnis;Nyköping: H. Höjer; Linköping health care region— Linköping: L. Baldetorp, T. Hatschek, and R. Sjödahl;Norrköping: G. Arbman; Motala: E. Nilsson; Finspång:V. Störgren-Fordell; Jönköping: A. Hugander andF. Lagerberg; Eksjö: G. Simert; Värnamo: R. Aubergde la Rüe; Västervik: Å. Aldman; Kalmar: O.Lannerstad; Oskarhamn: P. Gullstrand; Lund–Malmöhealth care region — Malmö: Å. Arwidi, M. Bohe,G. Ekelund, H. Jiborn, and T. Landberg; Lund: S. Graffman, O.Jansson, and B. Jeppson; Landskrona: R. Sörbris; Trelleborg:E. Ohlsson; Ystad: S. Lenninger; Hässleholm: K. Halldén;Halmstad: C. Norryd and S. Adamsen; Göteborg health careregion — Sahlgrenska: R. Hultborn; Östra: S. Nilsson;Uddevalla: O. Magnusson and H.-E. Söderberg; Kungälv:B. Lindberg and E. Tveit; Borås: R. Jansson and J.H. Svensson;Alingsås: Å. Gustafsson; Trollhättan: B. Almskogand H. Salander; Skövde: D. Holmlund; Lidköping: S.Filipsson; Falköping: R. Laino; Umeå health careregion — Umeå: L. Athlin and N.-O. Bengtsson; Skellefteå:G. Broman; Boden: G. Lundegård; Luleå: S. Dedorson;Gällivare: G. Henriksson; Piteå: A. Nordahl; Kalix:G. Ryd; Östersund: G. Edlund; Sundsvall: J.-O. Svensson;Örnsköldsvik: J. Rutegård; Härnösand:M. Fagerberg; Sollefteå: K. Edin; Executive Committee:B. Cedermark, B. Glimelius, I. Magnusson, L. Påhlman,L.E. Rutqvist, T. Theve, and N. Wilking; Writing Committee:B. Cedermark, M. Dahlberg, B. Glimelius, L. Påhlman, L.E.Rutqvist, and N. Wilking.
Radiotherapy for Rectal Cancer
Lavery I. C., Fazio V. W., Lopez-Kostner F., Vikram B., Heriot A. G., Cornes P., Glees J. P., Kumar D., Påhlman L., Glimelius B., The Swedish Rectal Cancer Trial Group
Extract |
Full Text
N Engl J Med 1997;
337:346-348, Jul 31, 1997.
Correspondence
This article has been cited by other articles:
Holmqvist, A., Gao, J., Adell, G., Carstensen, J., Sun, X.-F.
(2009). The location of lymphangiogenesis is an independent prognostic factor in rectal cancers with or without preoperative radiotherapy. Ann Oncol
0: mdp486v1-mdp486
[Abstract][Full Text]
DRZYMALA, M, HAWKINS, M A, HENRYS, A J, BEDFORD, J, NORMAN, A, TAIT, D M
(2009). The effect of treatment position, prone or supine, on dose-volume histograms for pelvic radiotherapy in patients with rectal cancer. Br. J. Radiol.
82: 321-327
[Abstract][Full Text]
Barbaro, B., Fiorucci, C., Tebala, C., Valentini, V., Gambacorta, M. A., Vecchio, F. M., Rizzo, G., Coco, C., Crucitti, A., Ratto, C., Bonomo, L.
(2009). Locally Advanced Rectal Cancer: MR Imaging in Prediction of Response after Preoperative Chemotherapy and Radiation Therapy. Radiology
250: 730-739
[Abstract][Full Text]
Castaldo, E. T., Parikh, A. A., Pinson, C. W., Feurer, I. D., Merchant, N. B.
(2009). Improvement of Survival With Response to Neoadjuvant Radiation Therapy for Rectal Cancer. Arch Surg
144: 129-134
[Abstract][Full Text]
Papamichael, D., Audisio, R., Horiot, J.-C., Glimelius, B., Sastre, J., Mitry, E., Van Cutsem, E., Gosney, M., Kohne, C.-H., Aapro, M.
(2009). Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol
20: 5-16
[Abstract][Full Text]
Zenilman, M. E.
(2008). Cyclooxygenase-2 Expression in Pretreatment Biopsy as a Predictor of Tumor Responses After Preoperative Chemoradiation in Rectal Cancer--Invited Critique. Arch Surg
143: 1097-1097
[Full Text]
Kornmann, M., Henne-Bruns, D., Porzsolt, F.
(2008). Neoadjuvant Treatment of Rectal Carcinoma: Assessment of Health Care Services by Physicians and Lay Persons. JCO
26: 4866-4868
[Full Text]
Assumpcao, L., Choti, M. A., Gleisner, A. L., Schulick, R. D., Swartz, M., Herman, J., Gearhart, S. L., Pawlik, T. M.
(2008). Patterns of Recurrence Following Liver Resection for Colorectal Metastases: Effect of Primary Rectal Tumor Site. Arch Surg
143: 743-749
[Abstract][Full Text]
MESSIOU, C, CHALMERS, A G, BOYLE, K, WILSON, D, SAGAR, P
(2008). Pre-operative MR assessment of recurrent rectal cancer. Br. J. Radiol.
81: 468-473
[Abstract][Full Text]
de Maat, M. F.G., van de Velde, C. J.H., van der Werff, M. P.J., Putter, H., Umetani, N., Klein-Kranenbarg, E. M., Turner, R. R., van Krieken, J. H. J.M., Bilchik, A., Tollenaar, R. A.E.M., Hoon, D. S.B.
(2008). Quantitative Analysis of Methylation of Genomic Loci in Early-Stage Rectal Cancer Predicts Distant Recurrence. JCO
26: 2327-2335
[Abstract][Full Text]
Kunnumakkara, A. B., Diagaradjane, P., Guha, S., Deorukhkar, A., Shentu, S., Aggarwal, B. B., Krishnan, S.
(2008). Curcumin Sensitizes Human Colorectal Cancer Xenografts in Nude Mice to {gamma}-Radiation by Targeting Nuclear Factor-{kappa}B-Regulated Gene Products. Clin. Cancer Res.
14: 2128-2136
[Abstract][Full Text]
Lee, S. H., Lee, K. C., Choi, J. H., Oh, J. H., Baek, J.-H., Park, S. H., Shin, D. B.
(2008). Chemoradiotherapy Followed by Surgery in Rectal Cancer: Improved Local Control Using a Moderately High Pelvic Radiation Dose. Jpn J Clin Oncol
0: hym164v1-10
[Abstract][Full Text]
Hohenberger, P., Wysocki, W. M.
(2008). Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Limbs: Which Treatment to Choose?. The Oncologist
13: 175-186
[Abstract][Full Text]
Muthusamy, V. R., Chang, K. J.
(2007). Optimal Methods for Staging Rectal Cancer. Clin. Cancer Res.
13: 6877s-6884s
[Abstract][Full Text]
de Heer, P., de Bruin, E. C., Klein-Kranenbarg, E., Aalbers, R. I.J.M., Marijnen, C. A.M., Putter, H., de Bont, H. J., Nagelkerke, J. F., van Krieken, J. H. J.M., Verspaget, H. W., van de Velde, C. J.H., Kuppen, P. J.K., for the Dutch Colorectal Cancer Group,
(2007). Caspase-3 Activity Predicts Local Recurrence in Rectal Cancer. Clin. Cancer Res.
13: 5810-5815
[Abstract][Full Text]
Nagtegaal, I. D., Gosens, M. J.E.M., Marijnen, C. A.M., Rutten, H. J., van de Velde, C. J.H., van Krieken, J. H. J.M.
(2007). Combinations of Tumor and Treatment Parameters Are More Discriminative for Prognosis Than the Present TNM System in Rectal Cancer. JCO
25: 1647-1650
[Full Text]
Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., Mayer, R. J.
(2007). Adjuvant Treatment of Colorectal Cancer. CA Cancer J Clin
57: 168-185
[Abstract][Full Text]
Machiels, J-P, Sempoux, C, Scalliet, P, Coche, J-C, Humblet, Y, Van Cutsem, E, Kerger, J, Canon, J-L, Peeters, M, Aydin, S, Laurent, S, Kartheuser, A, Coster, B, Roels, S, Daisne, J-F, Honhon, B, Duck, L, Kirkove, C, Bonny, M-A, Haustermans, K
(2007). Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol
18: 738-744
[Abstract][Full Text]
Allen, S. D., Padhani, A. R., Dzik-Jurasz, A. S., Glynne-Jones, R.
(2007). Rectal Carcinoma: MRI with Histologic Correlation Before and After Chemoradiation Therapy. Am. J. Roentgenol.
188: 442-451
[Abstract][Full Text]
Gill, S., Blackstock, A. W., Goldberg, R. M.
(2007). Colorectal Cancer. Mayo Clin Proc.
82: 114-129
[Abstract][Full Text]
Han, N., Galandiuk, S.
(2006). Induction Chemoradiation for Rectal Cancer. Arch Surg
141: 1246-1252
[Abstract][Full Text]
MERCURY Study Group,
(2006). Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ
333: 779-
[Abstract][Full Text]
Gerard, J.-P., Conroy, T., Bonnetain, F., Bouche, O., Chapet, O., Closon-Dejardin, M.-T., Untereiner, M., Leduc, B., Francois, E., Maurel, J., Seitz, J.-F., Buecher, B., Mackiewicz, R., Ducreux, M., Bedenne, L.
(2006). Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203. JCO
24: 4620-4625
[Abstract][Full Text]
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., Ollier, J.-C., EORTC Radiotherapy Group Trial 22921,
(2006). Chemotherapy with Preoperative Radiotherapy in Rectal Cancer. NEJM
355: 1114-1123
[Abstract][Full Text]
Capirci, C., Rubello, D., Chierichetti, F., Crepaldi, G., Fanti, S., Mandoliti, G., Salviato, S., Boni, G., Rampin, L., Polico, C., Mariani, G.
(2006). Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy.. Am. J. Roentgenol.
187: W202-W208
[Abstract][Full Text]
Dhamanaskar, K. P., Thurston, W., Wilson, S. R.
(2006). Transvaginal sonography as an adjunct to endorectal sonography in the staging of rectal cancer in women.. Am. J. Roentgenol.
187: 90-98
[Abstract][Full Text]
Calvo, F. A., Serrano, F. J., Diaz-Gonzalez, J. A., Gomez-Espi, M., Lozano, E., Garcia, R., de la Mata, D., Arranz, J. A., Garcia-Alfonso, P., Perez-Manga, G., Alvarez, E.
(2006). Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation. Ann Oncol
17: 1103-1110
[Abstract][Full Text]
Watanabe, T., Komuro, Y., Kiyomatsu, T., Kanazawa, T., Kazama, Y., Tanaka, J., Tanaka, T., Yamamoto, Y., Shirane, M., Muto, T., Nagawa, H.
(2006). Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles.. Cancer Res.
66: 3370-3374
[Abstract][Full Text]
Akasu, T., Moriya, Y., Ohashi, Y., Yoshida, S., Shirao, K., Kodaira, S., for the National Surgical Adjuvant Study of Colore,
(2006). Adjuvant Chemotherapy with Uracil-Tegafur for Pathological Stage III Rectal Cancer after Mesorectal Excision with Selective Lateral Pelvic Lymphadenectomy: A Multicenter Randomized Controlled Trial. Jpn J Clin Oncol
36: 237-244
[Abstract][Full Text]
Mohiuddin, M., Winter, K., Mitchell, E., Hanna, N., Yuen, A., Nichols, C., Shane, R., Hayostek, C., Willett, C.
(2006). Randomized Phase II Study of Neoadjuvant Combined-Modality Chemoradiation for Distal Rectal Cancer: Radiation Therapy Oncology Group Trial 0012. JCO
24: 650-655
[Abstract][Full Text]
De Paoli, A., Chiara, S., Luppi, G., Friso, M. L., Beretta, G. D., Del Prete, S., Pasetto, L., Santantonio, M., Sarti, E., Mantello, G., Innocente, R., Frustaci, S., Corvo, R., Rosso, R.
(2006). Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol
17: 246-251
[Abstract][Full Text]
Kalff, V., Duong, C., Drummond, E. G., Matthews, J. P., Hicks, R. J.
(2006). Findings on 18F-FDG PET Scans After Neoadjuvant Chemoradiation Provides Prognostic Stratification in Patients with Locally Advanced Rectal Carcinoma Subsequently Treated by Radical Surgery. JNM
47: 14-22
[Abstract][Full Text]
Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Gatter, K. C., Harris, A. L., for Tumour and Angiogenesis Research Group,
(2005). Inclusion of Vasculature-Related Variables in the Dukes Staging System of Colon Cancer. Clin. Cancer Res.
11: 8653-8660
[Abstract][Full Text]
Birgisson, H., Pahlman, L., Gunnarsson, U., Glimelius, B.
(2005). Adverse Effects of Preoperative Radiation Therapy for Rectal Cancer: Long-Term Follow-Up of the Swedish Rectal Cancer Trial. JCO
23: 8697-8705
[Abstract][Full Text]
Machiels, J.-P., Duck, L., Honhon, B., Coster, B., Coche, J.-C., Scalliet, P., Humblet, Y., Aydin, S., Kerger, J., Remouchamps, V., Canon, J.-L., Van Maele, P., Gilbeau, L., Laurent, S., Kirkove, C., Octave-Prignot, M., Baurain, J.-F., Kartheuser, A., Sempoux, C.
(2005). Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol
16: 1898-1905
[Abstract][Full Text]
Tait, D
(2005). Advances in chemoradiation therapy in rectal cancer: the impact of imaging. Br. J. Radiol.
78: S131-S137
[Full Text]
Birgisson, H., Pahlman, L., Gunnarsson, U., Glimelius, B.
(2005). Occurrence of Second Cancers in Patients Treated With Radiotherapy for Rectal Cancer. JCO
23: 6126-6131
[Abstract][Full Text]
Bosset, J.-F., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., Briffaux, A., Collette, L.
(2005). Enhanced Tumorocidal Effect of Chemotherapy With Preoperative Radiotherapy for Rectal Cancer: Preliminary Results--EORTC 22921. JCO
23: 5620-5627
[Abstract][Full Text]
Zlobec, I., Steele, R., Nigam, N., Compton, C. C.
(2005). A Predictive Model of Rectal Tumor Response to Preoperative Radiotherapy Using Classification and Regression Tree Methods. Clin. Cancer Res.
11: 5440-5443
[Abstract][Full Text]
Gaur, S., Shukla, V., Julianov, A., Ferretti, G., Bria, E., Mandala, M., Bujko, K., Nowacki, M. P., Kepka, L., Unnikrishnan, G., Dhar, P., Sudhindran, S., Sauer, R., Rodel, C.
(2005). Chemoradiotherapy for rectal cancer.. NEJM
352: 509-511
[Full Text]
Luccichenti, G., Cademartiri, F., Sianesi, M., Roncoroni, L., Pavone, P., Krestin, G. P.
(2005). Radiologic Assessment of Rectosigmoid Cancer Before and After Neoadjuvant Radiation Therapy: Comparison Between Quantitation Techniques. Am. J. Roentgenol.
184: 526-530
[Abstract][Full Text]
Akasu, T., Iinuma, G., Fujita, T., Muramatsu, Y., Tateishi, U., Miyakawa, K., Murakami, T., Moriyama, N.
(2005). Thin-Section MRI with a Phased-Array Coil for Preoperative Evaluation of Pelvic Anatomy and Tumor Extent in Patients with Rectal Cancer. Am. J. Roentgenol.
184: 531-538
[Abstract][Full Text]
Vliegen, R. F. A., Beets, G. L., von Meyenfeldt, M. F., Kessels, A. G. H., Lemaire, E. E. M. T., van Engelshoven, J. M. A., Beets-Tan, R. G. H.
(2005). Rectal Cancer: MR Imaging in Local Staging--Is Gadolinium-based Contrast Material Helpful?. Radiology
234: 179-188
[Abstract][Full Text]
Suzuki, T., Sadahiro, S., Fukasawa, M., Ishikawa, K., Kamijo, A., Yasuda, S., Makuuchi, H., Ohizumi, Y., Murayama, C.
(2004). Predictive Factors of Tumor Shrinkage and Histological Regression in Patients who Received Preoperative Radiotherapy for Rectal Cancer. Jpn J Clin Oncol
34: 740-746
[Abstract][Full Text]
Sauer, R., Becker, H., Hohenberger, W., Rodel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., Karstens, J.-H., Liersch, T., Schmidberger, H., Raab, R., the German Rectal Cancer Study Group,
(2004). Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. NEJM
351: 1731-1740
[Abstract][Full Text]
Madoff, R. D.
(2004). Chemoradiotherapy for Rectal Cancer -- When, Why, and How?. NEJM
351: 1790-1792
[Full Text]
Glehen, O., Kwiatkowski, F., Sugarbaker, P.H., Elias, D., Levine, E.A., De Simone, M., Barone, R., Yonemura, Y., Cavaliere, F., Quenet, F., Gutman, M., Tentes, A.A.K., Lorimier, G., Bernard, J.L., Bereder, J.M., Porcheron, J., Gomez-Portilla, A., Shen, P., Deraco, M., Rat, P.
(2004). Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional Study. JCO
22: 3284-3292
[Abstract][Full Text]
Tepper, J. E.
(2004). Patient Selection, Realism, and Randomized Clinical Trials. JCO
22: 3215-3217
[Full Text]
Crane, C. H., Sargent, D. J.
(2004). Substitution of Oral Fluoropyrimidines for Infusional Fluorouracil With Radiotherapy: How Much Data Do We Need?. JCO
22: 2978-2981
[Full Text]
Kulinna, C., Eibel, R., Matzek, W., Bonel, H., Aust, D., Strauss, T., Reiser, M., Scheidler, J.
(2004). Staging of Rectal Cancer: Diagnostic Potential of Multiplanar Reconstructions with MDCT. Am. J. Roentgenol.
183: 421-427
[Abstract][Full Text]
Beets-Tan, R. G. H., Beets, G. L.
(2004). Rectal Cancer: Review with Emphasis on MR Imaging. Radiology
232: 335-346
[Abstract][Full Text]
Gerard, J.-P., Chapet, O., Nemoz, C., Hartweig, J., Romestaing, P., Coquard, R., Barbet, N., Maingon, P., Mahe, M., Baulieux, J., Partensky, C., Papillon, M., Glehen, O., Crozet, B., Grandjean, J.-P., Adeleine, P.
(2004). Improved Sphincter Preservation in Low Rectal Cancer With High-Dose Preoperative Radiotherapy: The Lyon R96-02 Randomized Trial. JCO
22: 2404-2409
[Abstract][Full Text]
Kim, M.-J., Lim, J. S., Oh, Y. T., Kim, J. H., Chung, J.-J., Joo, S. H., Kim, N. K., Lee, K. Y., Kim, W. H., Kim, K. W.
(2004). Preoperative MRI of Rectal Cancer With and Without Rectal Water Filling: An Intraindividual Comparison. Am. J. Roentgenol.
182: 1469-1476
[Abstract][Full Text]
Filippone, A., Ambrosini, R., Fuschi, M., Marinelli, T., Genovesi, D., Bonomo, L.
(2004). Preoperative T and N Staging of Colorectal Cancer: Accuracy of Contrast-enhanced Multi-Detector Row CT Colonography--Initial Experience. Radiology
231: 83-90
[Abstract][Full Text]
Duff, S., Wood, C, McCredie, V, Levine, E, Saunders, M., O'Dwyer, S.
(2004). Waiting times for treatment of rectal cancer in North West England. JRSM
97: 117-118
[Abstract][Full Text]
Telford, J. J., Saltzman, J. R., Kuntz, K. M., Syngal, S.
(2004). Impact of Preoperative Staging and Chemoradiation Versus Postoperative Chemoradiation on Outcome in Patients With Rectal Cancer: A Decision Analysis. JNCI J Natl Cancer Inst
96: 191-201
[Abstract][Full Text]
Morris, A. M., Billingsley, K. G., Baxter, N. N., Baldwin, L.-M.
(2004). Racial Disparities in Rectal Cancer Treatment: A Population-Based Analysis. Arch Surg
139: 151-155
[Abstract][Full Text]
van den Brink, M., van den Hout, W. B., Stiggelbout, A. M., Klein Kranenbarg, E., Marijnen, C. A.M., van de Velde, C. J.H., Kievit, J.
(2004). Cost-Utility Analysis of Preoperative Radiotherapy in Patients With Rectal Cancer Undergoing Total Mesorectal Excision: A Study of the Dutch Colorectal Cancer Group. JCO
22: 244-253
[Abstract][Full Text]
Simunovic, M., Gafni, A., Levine, M.
(2004). Economics of Preoperative Radiotherapy With Total Mesorectal Excision: What Can We Learn From the Dutch Experience?. JCO
22: 217-219
[Full Text]
Hodgson, D. C., Zhang, W., Zaslavsky, A. M., Fuchs, C. S., Wright, W. E., Ayanian, J. Z.
(2003). Relation of Hospital Volume to Colostomy Rates and Survival for Patients With Rectal Cancer. JNCI J Natl Cancer Inst
95: 708-716
[Abstract][Full Text]
Ghadimi, B. M., Grade, M., Liersch, T., Langer, C., Siemer, A., Fuzesi, L., Becker, H.
(2003). Gain of Chromosome 8q23-24 Is a Predictive Marker for Lymph Node Positivity in Colorectal Cancer. Clin. Cancer Res.
9: 1808-1814
[Abstract][Full Text]
Brown, G., Richards, C. J., Bourne, M. W., Newcombe, R. G., Radcliffe, A. G., Dallimore, N. S., Williams, G. T.
(2003). Morphologic Predictors of Lymph Node Status in Rectal Cancer with Use of High-Spatial-Resolution MR Imaging with Histopathologic Comparison. Radiology
227: 371-377
[Abstract][Full Text]
Ito, Y., Ohtsu, A., Ishikura, S., Boku, N., Nihei, K., Ogino, T., Ikeda, H.
(2003). Efficacy of Chemoradiotherapy on Pain Relief in Patients with Intrapelvic Recurrence of Rectal Cancer. Jpn J Clin Oncol
33: 180-185
[Abstract][Full Text]
Gerard, J.-P., Chapet, O., Nemoz, C., Romestaing, P., Mornex, F., Coquard, R., Barbet, N., Atlan, D., Adeleine, P., Freyer, G.
(2003). Preoperative Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer With High-Dose Radiation and Oxaliplatin-Containing Regimen: The Lyon R0-04 Phase II Trial. JCO
21: 1119-1124
[Abstract][Full Text]
Saunders, T H, Mendes Ribeiro, H K, Gleeson, F V
(2002). New techniques for imaging colorectal cancer: the use of MRI, PET and radioimmunoscintigraphy for primary staging and follow-up. Br Med Bull
64: 81-99
[Abstract][Full Text]
Dorudi, S., Steele, R. J., McArdle, C. S
(2002). Surgery for colorectal cancer. Br Med Bull
64: 101-118
[Abstract][Full Text]
Glimelius, B.
(2002). Radiotherapy in rectal cancer. Br Med Bull
64: 141-157
[Abstract][Full Text]
Leslie, A, Steele, R J C
(2002). Management of colorectal cancer. Postgrad. Med. J.
78: 473-478
[Abstract][Full Text]
Minsky, B. D.
(2002). Sphincter Preservation for Rectal Cancer: Fact or Fiction?. JCO
20: 1971-1972
[Full Text]
Tepper, J.E., O'Connell, M., Niedzwiecki, D., Hollis, D.R., Benson, A.B. III, Cummings, B., Gunderson, L.L., Macdonald, J.S., Martenson, J.A., Mayer, R.J.
(2002). Adjuvant Therapy in Rectal Cancer: Analysis of Stage, Sex, and Local Control--Final Report of Intergroup 0114. JCO
20: 1744-1750
[Abstract][Full Text]
Lee, J.-H., Lee, J.-H., Ahn, J.-H., Bahng, H., Kim, T.-W., Kang, Y.-K., Lee, K.-H., Kim, J.-C., Yu, C.-S., Kim, J.-H., Ahn, S.-D., Kim, W.-K., Kim, S.-H., Lee, J.-S.
(2002). Randomized Trial of Postoperative Adjuvant Therapy in Stage II and III Rectal Cancer to Define the Optimal Sequence of Chemotherapy and Radiotherapy: A Preliminary Report. JCO
20: 1751-1758
[Abstract][Full Text]
Gagliardi, G., Bayar, S., Smith, R., Salem, R. R.
(2002). Preoperative Staging of Rectal Cancer Using Magnetic Resonance Imaging With External Phase-Arrayed Coils. Arch Surg
137: 447-451
[Abstract][Full Text]
Marijnen, C. A.M., Kapiteijn, E., van de Velde, C. J.H., Martijn, H., Steup, W. H., Wiggers, T., Kranenbarg, E. K., Leer, J. W.H.
(2002). Acute Side Effects and Complications After Short-Term Preoperative Radiotherapy Combined With Total Mesorectal Excision in Primary Rectal Cancer: Report of a Multicenter Randomized Trial. JCO
20: 817-825
[Abstract][Full Text]
Lawes, D, Boulos, P B
(2002). Advances in the management of rectal cancer. JRSM
95: 587-590
[Full Text]
Akahoshi, K, Yoshinaga, S, Soejima, A, Nagaie, T, Koyanagi, N, Nakanishi, K, Harada, N, Nawata, H
(2001). Transit endoscopic ultrasound of colorectal cancer using a 12 MHz catheter probe. Br. J. Radiol.
74: 1017-1022
[Abstract][Full Text]
Stocchi, L., Nelson, H., Sargent, D. J., O'Connell, M. J., Tepper, J. E., Krook, J. E., Beart, R. Jr
(2001). Impact of Surgical and Pathologic Variables in Rectal Cancer: A United States Community and Cooperative Group Report. JCO
19: 3895-3902
[Abstract][Full Text]
Tepper, J. E.
(2001). Adjuvant Radiation Therapy of Rectal Cancer. JCO
19: 3709-3711
[Full Text]
Schrag, D., Gelfand, S. E., Bach, P. B., Guillem, J., Minsky, B. D., Begg, C. B.
(2001). Who Gets Adjuvant Treatment for Stage II and III Rectal Cancer? Insight From Surveillance, Epidemiology, and End Results-Medicare. JCO
19: 3712-3718
[Abstract][Full Text]
Kapiteijn, E., Marijnen, C. A.M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J.T., Pahlman, L., Glimelius, B., van Krieken, J. H. J.M., Leer, J. W.H., van de Velde, C. J.H., the Dutch Colorectal Cancer Group,
(2001). Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer. NEJM
345: 638-646
[Abstract][Full Text]
Nelson, H., Sargent, D. J.
(2001). Refining Multimodal Therapy for Rectal Cancer. NEJM
345: 690-692
[Full Text]
Glynne-Jones, R., Debus, J.
(2001). Improving Chemoradiotherapy in Rectal Cancer. The Oncologist
6: 29-34
[Abstract][Full Text]
Marijnen, C.A.M., Nagtegaal, I.D., Kranenbarg, E. K., Hermans, J., van de Velde, C.J.H., Leer, J.W.H., van Krieken, J.H.J.M.
(2001). No Downstaging After Short-Term Preoperative Radiotherapy in Rectal Cancer Patients. JCO
19: 1976-1984
[Abstract][Full Text]
Gervaz, P., Rotholtz, N., Pisano, M., Kaplan, E., Secic, M., Coucke, P., Pikarsky, A., Efron, J., Weiss, E., Wexner, S.
(2001). Quantitative Short-term Study of Anal Sphincter Function After Chemoradiation for Rectal Cancer. Arch Surg
136: 192-196
[Abstract][Full Text]
Guadagni, S., Fiorentini, G., Palumbo, G., Valenti, M., Russo, F., Cantore, M., Deraco, M., Vaglini, M., Amicucci, G.
(2001). Hypoxic Pelvic Perfusion With Mitomycin C Using a Simplified Balloon-Occlusion Technique in the Treatment of Patients With Unresectable Locally Recurrent Rectal Cancer. Arch Surg
136: 105-112
[Abstract][Full Text]
Camma, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxi, A., Cottone, M.
(2000). Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-analysis. JAMA
284: 1008-1015
[Abstract][Full Text]
Lammering, G., Taher, M. M., Gruenagel, H.-H., Borchard, F., Porschen, R.
(2000). Alteration of DNA Ploidy Status and Cell Proliferation Induced by Preoperative Radiotherapy Is a Prognostic Factor in Rectal Cancer. Clin. Cancer Res.
6: 3215-3221
[Abstract][Full Text]
Haller, D. G.
(2000). Defining the Optimal Therapy for Rectal Cancer. JNCI J Natl Cancer Inst
92: 361-362
[Full Text]
TORTOLANI, P. J., KAUFMAN, H. S., NAHABEDIAN, M. Y., FRASSICA, F. J.
(1999). Pericapsular Fistula of the Hip After Radiation Therapy and Resection of a Rectal Carcinoma. A Case Report. JBJS
81: 1596-9
[Full Text]
Francois, Y., Nemoz, C. J., Baulieux, J., Vignal, J., Grandjean, J.-P., Partensky, C., Souquet, J. C., Adeleine, P., Gerard, J.-P.
(1999). Influence of the Interval Between Preoperative Radiation Therapy and Surgery on Downstaging and on the Rate of Sphincter-Sparing Surgery for Rectal Cancer: The Lyon R90-01 Randomized Trial. JCO
17: 2396-2396
[Abstract][Full Text]
Blomqvist, P, Ekbom, A, Nyren, O, Krusemo, U B, Bergstrom, R, Adami, H-O
(1999). Survival after rectal cancer: differences between hospital catchment areas. A nationwide study in Sweden. Gut
45: 39-44
[Abstract][Full Text]
Brown, G., Richards, C. J., Newcombe, R. G., Dallimore, N. S., Radcliffe, A. G., Carey, D. P., Bourne, M. W., Williams, G. T.
(1999). Rectal Carcinoma: Thin-Section MR Imaging for Staging in 28 Patients. Radiology
211: 215-222
[Abstract][Full Text]
Finn-Faivre, C, Maurel, J, Benhamiche, A M, Herbert, C, Mitry, E, Launoy, G, Faivre, J
(1999). Evidence of improving survival of patients with rectal cancer in France: a population based study. Gut
44: 377-381
[Abstract][Full Text]
Lavery, I. C., Fazio, V. W., Lopez-Kostner, F., Vikram, B., Heriot, A. G., Cornes, P., Glees, J. P., Kumar, D., Pahlman, L., Glimelius, B., The Swedish Rectal Cancer Trial Group,
(1997). Radiotherapy for Rectal Cancer. NEJM
337: 346-348
[Full Text]
Minsky, B. D.
(1997). Adjuvant Therapy for Rectal Cancer -- A Good First Step. NEJM
336: 1016-1017
[Full Text]
A correction has been published: N Engl J Med 1997;336(21):1539.
Previous
